Former New England Patriots quarterback Tom Brady didn’t go quietly into that good night after being the recipient of a good ...

Eli Owns is one of Michigan's longest-tenured commitments of the 2025 class. He committed to the Wolverines back in January ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

The unscripted market might be beginning to settle after a chaotic few years, but the over-reliance on recommissions needs to ...

People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...

Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.

One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...

Owens made a surprise commitment to the Wolverines between the Rose Bowl and the national championship game. He’s since been ...

A $2.25 million settlement has been approved in a wrongful-death lawsuit brought against Dakota County and three employees by ...